Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone510-848-5100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$330,000.00
Profitability
Miscellaneous
Employees170
OptionableOptionable
Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions
What is Dynavax Technologies' stock symbol?
Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."
How were Dynavax Technologies' earnings last quarter?
Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings data on Monday, November, 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.08. The biopharmaceutical company had revenue of $1.46 million for the quarter, compared to analysts' expectations of $3.16 million. Dynavax Technologies had a negative return on equity of 97.79% and a negative net margin of 5,044.85%. The firm's revenue for the quarter was up 2822.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.38) EPS. View Dynavax Technologies' Earnings History.
When is Dynavax Technologies' next earnings date?
What price target have analysts set for DVAX?
4 brokerages have issued 1-year target prices for Dynavax Technologies' stock. Their forecasts range from $25.00 to $32.00. On average, they anticipate Dynavax Technologies' share price to reach $28.00 in the next twelve months. This suggests a possible upside of 131.6% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.
What is the consensus analysts' recommendation for Dynavax Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.
What are Wall Street analysts saying about Dynavax Technologies stock?
Here are some recent quotes from research analysts about Dynavax Technologies stock:
- 1. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (12/31/2018)
- 2. Cantor Fitzgerald analysts commented, "Dynavax’s approved product, HEPLISAV-B, is a TLR9 agonist (1018 ISS) combined with recombinant Hepatitis surface Antigen (rHBsAg) used to vaccinate adults for the prophylaxis of HBV infection. When compared with existing vaccines, HEPLISAV-B has demonstrated higher protection in general patient groups and in high-risk patient populations, with a significantly more convenient dosing profile. HEPLISAV-B was approved on November 9, 2017." (10/19/2018)
Has Dynavax Technologies been receiving favorable news coverage?
Media coverage about DVAX stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dynavax Technologies earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Who are some of Dynavax Technologies' key competitors?
Some companies that are related to Dynavax Technologies include HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Endo International (ENDP), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX) and Ironwood Pharmaceuticals (IRWD).
Who are Dynavax Technologies' key executives?
Dynavax Technologies' management team includes the folowing people:
- Mr. Eddie Gray, CEO & Director (Age 60)
- Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 72)
- Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 67)
- Mr. David F. Novack, Sr. VP of Operations & Quality (Age 57)
- Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 72)
Who are Dynavax Technologies' major shareholders?
Dynavax Technologies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.02%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach, Robert Coffman and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.
Which major investors are buying Dynavax Technologies stock?
How do I buy shares of Dynavax Technologies?
Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dynavax Technologies' stock price today?
One share of DVAX stock can currently be purchased for approximately $12.09.
How big of a company is Dynavax Technologies?
Dynavax Technologies has a market capitalization of $754.80 million and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-95,150,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Dynavax Technologies employs 170 workers across the globe.
What is Dynavax Technologies' official website?
How can I contact Dynavax Technologies?
Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]
MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
